

Table 1. Baseline characteristics of healthy control individuals and patients with biopsy-proven NAFLD

Parameter	Controls (n=58)	NAFLD (n=349)	P-value
<b>Clinical and laboratory parameters</b>			
Age (years)	46.6 ± 9.2	40.2 ± 12.5	<0.001
Male (%)	45 (77.6%)	267 (76.5%)	0.857
Diabetes (%)	20 (34.5%)	110 (31.5%)	0.654
Hypertension (%)	22 (37.9%)	122 (35.0%)	0.661
Waist circumference (cm)	86.6 ± 7.0	92.1 ± 8.7	<0.001
BMI (kg/m <sup>2</sup> )	24.9 ± 2.6	26.8 ± 3.3	<0.001
RBC (10 <sup>12</sup> /L)	4.9 ± 0.5	5.0 ± 0.5	0.098
Hemoglobin (g/L)	145.5 ± 14.2	148.6 ± 14.1	0.121
WBC (10 <sup>9</sup> /L)	6.0 ± 1.7	6.2 ± 1.4	0.238
PLT (10 <sup>9</sup> /L)	235.4 ± 73.0	242.1 ± 58.8	0.44
ALT (U/L)	39.8 ± 46.9	80.5 ± 76.4	<0.001
AST (U/L)	32.8 ± 33.2	47.9 ± 31.8	0.001
GGT (U/L)	61.5 ± 83.8	77.4 ± 101.3	0.257
Albumin (g/L)	45.5 ± 3.0	46.6 ± 4.0	0.058
Uric acid (µmol/L)	364.8 ± 99.2	400.5 ± 102.9	0.014
Total cholesterol (mmol/L)	5.0 ± 1.2	5.1 ± 1.1	0.605
HDL cholesterol (mmol/L)	1.1 ± 0.2	1.0 ± 0.2	0.241
LDL cholesterol (mmol/L)	3.0 ± 0.9	3.1 ± 0.9	0.351
Triglycerides (mmol/L)	2.1 ± 1.5	2.3 ± 1.5	0.334
HbA1c (%)	6.4 ± 1.8	6.1 ± 1.2	0.114
Fasting glucose (mmol/L)	5.8 ± 1.9	5.6 ± 1.5	0.403
<b>Non-invasive markers</b>			
Fatty liver index	43.8 ± 21.5	62.8 ± 23.0	<0.001
Hepatic steatosis index	35.4 ± 4.0	40.4 ± 5.7	<0.001
<b><i>PNPLA3</i> I148M polymorphism</b>			0.051
CC	24 (42.86%)	94 (28.4%)	
CG	24 (42.86%)	152 (45.9%)	
GG	8 (14.29%)	85 (25.7%)	

Categorical values are shown as n (%). Continuous variables are shown as mean ± SD